[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Morsi A, Abd El-Ghani Ael-G, El-Shafiey M, Fawzy M, Ismail H, Monir M: Clinico-pathological features and outcome of management of pediatric gastrointestinal lymphoma. J Egypt Natl Canc Inst; 2005 Dec;17(4):251-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological features and outcome of management of pediatric gastrointestinal lymphoma.
  • PURPOSE: The purpose of this study is to evaluate pediatric GIT lymphomas as regards clinico-pathological features, controversies in surgical treatment, role of chemotherapy and the prognostic features.
  • PATIENTS AND METHODS: This study included forty three patients with pediatric GIT Non-Hodgkin's lymphoma collected over 7 years at the NCI Cairo University between January 1997 and December 2003.
  • The data of every patient included: Age, sex, presenting symptoms and signs, preoperative investigations, extent of the disease at diagnosis and the type of resection performed, histopathological examination, details of chemotherapy and state at follow up.
  • Overall and disease free survival were calculated and correlated with all parameters.
  • The lesions were located in the small intestine (n=15), the large intestine (n=14), the ileocecal region (n=10), stomach (n=2), and multifocally (n=2).
  • Burkitt's lymphoma was the commonest histological type (n=24).
  • All patients received a sort of systemic chemotherapy.
  • The only parameters that had significantly affected the overall survival were localized disease, complete resection, earlier stage and response to chemotherapy with p values, (0.005, 0.001, 0.005 and <0.001 respectively).
  • As regards the disease free survival the only significant factor was localized disease (p=0.035).
  • CONCLUSION: The extent of disease at presentation is the most important prognostic factor in pediatric GIT lymphoma.
  • Surgery still plays an important role such as complete resection in localized disease, management of complicated disease and diagnostic biopsy.
  • Chemotherapy represents a cornerstone in the treatment and offers an excellent chance for long term, disease free survival.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102814.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


2. Nomura K, Tomikashi K, Matsumoto Y, Yoshida N, Okuda T, Sakakura C, Mitsufuji S, Horiike S, Yamagishi H, Okanoue T, Taniwaki M: Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy. World J Gastroenterol; 2005 Jul 28;11(28):4443-4
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.
  • Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction.
  • A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall.
  • We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses.
  • Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2.
  • Rituximab may be effective as adjuvant therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Humans. Male. Remission Induction. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038051.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC4434679
  •  go-up   go-down


3. Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B: Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. Croat Med J; 2002 Oct;43(5):555-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.
  • AIM: To evaluate the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin s lymphoma in our institution.
  • METHOD: The retrospective study included 79 patients with a histologically confirmed primary gastrointestinal lymphoma, who were diagnosed and treated for the disease in the 1978-1997 period.
  • According to the treatment modality, the patients were divided into surgically treated and surgically non-treated group.
  • RESULTS: The stomach was the primary site of non-Hodgkin s lymphoma in 45 (57%) patients, small intestine in 19 (24%), and colon in 9 (11%) patients.
  • Six patients (8%) had multifocal disease.
  • Aggressive histology was found in 51 cases (65%), and low grade mucosa-associated lymphoid tissue (MALT) lymphoma in 28 (35%).
  • Helicobacter pylori infection was registered in 20 out of 45 patients with gastric lymphoma.
  • Twenty-six (33%) patients underwent surgical resection followed by chemotherapy, 47 (59%) were treated with chemotherapy alone, and 6 (8%) received antibiotics plus chemotherapy.
  • Eighteen patients (23%) experienced progressive disease.
  • Patients with gastric lymphoma had better OS and EFS than patients with primary lymphoma at other sites (65% vs 42%, and 62 vs 28%, respectively) (p=0.005).
  • Patients with early-stage disease had significantly better OS and PFS than patients with advanced-stage disease (p=0.048).
  • CONCLUSION: Primary gastrointestinal lymphoma can be successfully treated with chemotherapy alone but surgery remains an important therapeutic option for emergency problems.
  • The main prognostic factors were primary tumor site and extent of the disease.
  • [MeSH-major] Colonic Neoplasms / surgery. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402395.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


Advertisement
4. Meral M, Demirpençe M, Gönen C, Akarsu M, Kayahan H, Demirkan F, Kargi A, Akpinar H: Diffuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol; 2008 Jun;19(2):117-20
Hazardous Substances Data Bank. Barium, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse gastrointestinal involvement of mantle cell lymphoma.
  • The gastrointestinal tract is the predominant site of appearance of extranodal non-Hodgkin lymphomas.
  • The most frequent endoscopic finding of mantle cell lymphoma is multiple lymphomatous polyposis, which is a very rare entity.
  • Multiple lymphomatous polyposis is characterized by multiple polypoid lesions involving long segments of the gastrointestinal tract and it accounts for 2% of primary gastrointestinal tract lymphomas.
  • Gastrointestinal mantle cell lymphoma was confirmed with histopathological and immunohistochemical studies on biopsy specimens from colon, small intestine and stomach.
  • The patient was successfully treated by combination chemotherapy.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Polyposis / diagnosis. Lymphoma, Mantle-Cell / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Barium. Biopsy. Colon / pathology. Contrast Media. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Endoscopy, Digestive System. Humans. Intestine, Small / pathology. Male. Prednisolone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110668.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Contrast Media; 24GP945V5T / Barium; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


5. Tauro LF, Furtado HW, Aithala PS, D'Souza CS, George C, Vishnumoorthy SH: Primary lymphoma of the colon. Saudi J Gastroenterol; 2009 Oct-Dec;15(4):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the colon.
  • Primary lymphoma of the colon is a rare tumor of the gastrointestinal (GI) tract and comprises only 0.2-1.2% of all colonic malignancies.
  • The most common variety of colonic lymphoma is non-Hodgkin's lymphoma (NHL).
  • The stomach is the most common location of GI lymphomas, followed by the small intestine.
  • Early diagnosis may prevent intestinal perforation; however, the diagnosis is often delayed in most cases.
  • Therapeutic approaches described in two subsets include: Radical tumor resection (hemicolectomy) plus multi-agent chemotherapy (polychemotherapy) in early stage patients, biopsy plus multidrug chemotherapy in advanced stage patients.
  • Radiotherapy is reserved for specific cases; surgery alone can be considered as an adequate treatment for patients with low-grade NHL disease that does not infiltrate beyond the sub mucosa.
  • Although resection plays an important role in the local control of the disease and in preventing bleeding and/or perforation, it rarely eradicates the lymphoma by itself.
  • Those with limited stage disease may enjoy prolonged survival when treated with aggressive chemotherapy.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Am J Surg. 2009 Jan;197(1):e11-2 [18723150.001]
  • [Cites] Int Surg. 2001 Jan-Mar;86(1):20-5 [11890335.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):291-7 [8071513.001]
  • [Cites] Leuk Lymphoma. 1995 Nov;19(5-6):461-6 [8590847.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):22-33 [16502482.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Am Surg. 2008 Mar;74(3):214-6 [18376684.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):1005-6; discussion 1006 [18565526.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):257-62 [10962456.001]
  • (PMID = 19794280.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2981851
  •  go-up   go-down


6. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • Forty patients with primary NHL in the small and large intestine were studied retrospectively.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Radić-Kristo D, Planinc-Peraica A, Ostojić S, Vrhovac R, Kardum-Skelin I, Jaksić B: Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics. Coll Antropol; 2010 Jun;34(2):413-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics.
  • Primary non-Hodgkin lymphomas of gastrointestinal tract (PGI-NHL) are the most common extranodal lymphomas with an increasing incidence.
  • The incidence, clinicopathologic characteristics, treatment and survival were assessed in 39 successive, newly diagnosed PGI-NHL patients (23 male and 16 female) treated at "Merkur" University Hospital.
  • The most common site of PGI-NHL was stomach (n = 29, 74%), followed by small intestine (n = 5, 13%), and colon and rectosigmoid (n = 5, 13%).
  • According to World Health Organization (WHO) classification, 29 (87%) patients had diffuse large B-cell lymphoma (DLCBL), two had mantle cell lymphoma, and seven (18%) had marginal zone B-cell lymphoma-mucosa associated tissue (MALT).
  • Twenty-six (66%) patients underwent surgical resection followed by chemotherapy, ten (26%) were treated with chemotherapy alone, and three (8%) were treated surgically.
  • Four (10%) patients had progressive disease.
  • In our patients, the major prognostic factor for outcome was the stage of disease.
  • Patients with localized lymphoma (stage IE and IIE) had a significantly longer overall survival: 85% at five years and 65% at ten years.
  • Patients with extended disease (stage IIIE and IVE) had overall survival less than 33%.
  • Disease stage and LDH were the only parameters that had a statistically significant effect patient survival.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / epidemiology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Female. Humans. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Rectal Neoplasms / epidemiology. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Retrospective Studies. Sigmoid Neoplasms / epidemiology. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Survival Rate. Young Adult


8. Brueck M, Barton M, Rauber K, Zikova A, Kramer W: [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)]. Dtsch Med Wochenschr; 2001 Dec 7;126(49):1391-5
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)].
  • [Transliterated title] Dünndarmileus bei intestinalem Marginalzonen-B-Zell-Lymphom des MALT.
  • HISTORY AND ADMISSION FINDINGS: A 67-year-old man had complained of diffuse abdominal pain and constipation for 4 days without indication of any underlying disease.
  • INVESTIGATIONS: Physical examination revealed signs of an acute abdomen with high-pitched bowel sounds and diffuse abdominal guarding.
  • The X-ray showed ileus of the small intestine which required emergency laparotomy.
  • It was removed by partial resection of the small intestine.
  • DIAGNOSIS: Ileus of the small intestine with a low-malignant marginal zone B-cell (non-Hodgkin) lymphoma of MALT type (mucoid-associated lymphoid tissue).
  • TREATMENT AND COURSE: Postoperative staging indicated no further manifestation of the lymphoma.
  • As no radical operation in resecting the tumour had been performed, combined radio- and chemotherapy was undertaken.
  • CONCLUSION: Marginal B-cell lymphomas of the small intestine are only rarely seen in central Europe.
  • Despite its usually slow growth this non-Hodgkin lymphoma of low malignancy can produce an acute mechanical ileus without prodromal symptoms.
  • A multimodal therapeutic approach is often employed, but there are no established treatment strategies.
  • [MeSH-major] Ileal Diseases / etiology. Intestinal Neoplasms / diagnosis. Intestinal Obstruction / etiology. Lymphoma, B-Cell, Marginal Zone / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11740631.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Huang GT, Zhu GH: [Experience of the diagnosis and treatment of primary small intestine lymphoma]. Zhonghua Wai Ke Za Zhi; 2010 Jan 1;48(1):45-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of the diagnosis and treatment of primary small intestine lymphoma].
  • OBJECTIVE: To report the experiences of the diagnosis and treatment of primary lymphoma of the small intestine (PSIL).
  • Data of gender, age, clinical manifestation, laboratory examination, imageology examination, diagnosis and treatment of the patients was reviewed.
  • RESULTS: The most common clinical manifestations were as follow: abdominal pain, abdominal lump, bowel obstruction, gastrointestinal hemorrhage and athrepsy.
  • All the patients were diagnosed as non-Hodgkin lymphoma (NHL) by postoperative pathology (8 patients as diffuse large B-cell lymphoma, 5 as mucosa associated lymphoid tissue type B cell lymphoma and 2 as enteropathy-type intestinal T cell lymphoma).
  • Ten patients received adjuvant chemotherapy with the regimen of CHOP (cyclophosphamide + epirubicin + vincristine + prednisone) after the operation.
  • Fourteen cases were followed-up for a mean time of 30 months (range, 6 - 52 months).
  • Operation combined with chemotherapy is important for PSIL.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small / pathology. Lymphoma / diagnosis. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302754.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Khomov DA, Sinev IuV, Sotnikov VM: [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy]. Vestn Rentgenol Radiol; 2008;(2-3):43-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy].
  • The paper describes the experience in using capsule endoscopy to diagnose small bowel lesions during and after chemoradiation therapy in patients with diagnosed Hodgkin's lymphoma and an attempt to compare the current views of normal tissue response to ionizing radiation, as well as drugs used for chemotherapy.
  • [MeSH-major] Capsule Endoscopy. Hodgkin Disease / therapy. Intestinal Diseases / pathology. Intestine, Small / pathology
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Humans. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21337763.001).
  • [ISSN] 0042-4676
  • [Journal-full-title] Vestnik rentgenologii i radiologii
  • [ISO-abbreviation] Vestn Rentgenol Radiol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • The major symptoms included abdominal pain and intestinal obstruction.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • Fourteen patients were treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, and 8 patients were treated with Rituximab at the same time.
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520384.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T: [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):142-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.
  • METHODS: The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed.
  • RESULTS: The most frequently site of the lesions in the 32 patients was the large intestine (n = 16, 50.0%), followed by small intestine (n = 8, 25.0%), ileocaecal region (n = 6, 18.8%) and multiple intestinal sites (n = 2, 6.2%).
  • Twenty-one patients (65.6%) were diagnosed as B-cell lymphoma, 15 (46.9%) were diffuse large B-cell lymphoma.
  • Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma.
  • Twenty-nine patients were treated initially by surgery with or without chemotherapy, 19 of them (59.4%) achieved complete response.
  • Based on Cox multivariate analysis, stage III - IV, B symptoms and T cell phenotype of the disease were the independent adverse prognostic factors (P < 0.05).
  • CONCLUSION: The clinical presentation of primary intestinal non-Hodgkin's lymphoma are not specific clinically.
  • Most of the histological types are diffuse large B-cell type lymphoma.
  • Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease.
  • The prognosis of this disease are correlated with the stage, B symptoms and T cell phenotype.
  • [MeSH-major] Intestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750023.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Koh PK, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW: Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998). Int J Oncol; 2001 Apr;18(4):743-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998).
  • Extranodal non-Hodgkin's lymphoma (NHL) of the gastrointestinal tract accounts for about one third of all extranodal NHL.
  • We retrospectively reviewed the clinical and histopathologic records of 71 patients with stage IE and IIE primary gastrointestinal NHL referred to the Sheffield Lymphoma Group (SLG) from 1989 to 1998.
  • The most common primary site was the stomach (45 patients, 63% of all cases), followed by the small intestine (16, 23%) and large intestine (9, 13%).
  • Mucosa-associated lymphoid tissue (MALT) lymphomas were the largest histologic subtype seen (57%), with 87% of these arising from the stomach; next most frequent was the diffuse large B-cell subtype (21% of all cases) most frequently arising from the intestine (60%).
  • For treatment of gastric MALT lymphoma, a combined approach (surgery followed by chemotherapy, antihelicobacter therapy followed by chemotherapy) was favoured (22 cases).
  • Knowledge of the Revised European American Lymphoma classification and the Helicobacter pylori/MALT association has influenced treatment approaches over the 10-year study period.
  • For small intestinal lymphoma, surgery (with or without chemotherapy) gave 5- and 10-year survivals of 60%.
  • Overall survival of patients with primary gastrointestinal lymphoma managed by the SLG is similar to that reported from other large series.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Great Britain. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251169.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


14. Tamura H, Ogata K, Kondo A, Wakita T, Inami M, Mizuki T, Hyodo H, Shioi Y, Nakamura K, Mitsui K, Tanaka S, Sakamoto C, Dan K: [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma]. Rinsho Ketsueki; 2007 Jun;48(6):510-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma].
  • Primary small intestinal lymphoma (PSIL) is a relatively rare form of non-Hodgkin lymphoma, often complicated by bleeding, obstruction, or perforation of the intestine during the clinical course.
  • The initial diagnosis and management of these complications are often difficult in PSIL, because the small intestine is usually inaccessible in routine endoscopy.
  • Recently, total enteroscopy with a double-balloon method, called double balloon endoscopy (DBE), has been developed for the diagnosis and treatment of small intestinal disorders.
  • In these cases, DBE was useful in the diagnosis, decision to perform surgery after assessment of bleeding lesion, and treatment of the intestinal stenosis using enteroscopic balloon dilatation.
  • Combination chemotherapy consisting of anthracycline, cyclophosphamide, vincristine, and prednisolone with rituximab was administered in 3 cases, and all achieved complete remission.
  • More PSIL cases must be analyzed to establish the optimal management of patients with this form of lymphoma.
  • [MeSH-major] Catheterization / methods. Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633101.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


15. Hata S, Pietsch J, Shankar S: Intestinal complications in children undergoing chemotherapy for mediastinal non-Hodgkin's lymphoma. Pediatr Hematol Oncol; 2004 Dec;21(8):707-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal complications in children undergoing chemotherapy for mediastinal non-Hodgkin's lymphoma.
  • Toxicities involving gastrointestinal tract are common in patients undergoing aggressive chemotherapy for cancer.
  • However, it is uncommon to develop severe ulceration or perforation of the small intestine in absence of direct involvement of the bowel with the malignancy.
  • The authors describe two children who developed severe gastrointestinal complications requiring surgical intervention following initial chemotherapy for non-Hodgkin's lymphoma.
  • Both patients had no evidence of small bowel involvement by lymphoma on clinical staging.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Intestinal Diseases / chemically induced. Lymphoma, Non-Hodgkin / complications. Mediastinal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739625.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


16. Piscaglia AC, Campanale M, Gasbarrini G: Small bowel nonendocrine neoplasms: current concepts and novel perspectives. Eur Rev Med Pharmacol Sci; 2010 Apr;14(4):320-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel nonendocrine neoplasms: current concepts and novel perspectives.
  • Although small bowel nonendocrine neoplasms are rare, their incidence has increased dramatically over the past 30 years.
  • Small bowel malignacies can be classified depending upon their cellular origin into four principal histotypes: carcinoid tumors, adenocarcinomas, lymphomas and mesenchymal tumors.
  • Until a few years ago, the treatment of small bowel tumors had remained relatively unchanged, with little progress in the development of effective adjuvant therapies and in the improvement of long-term survival over time.
  • Recently, the growing interest in the understanding of the mechanisms underlying carcinogenesis has offered novel insights for the diagnosis and therapy of small bowel tumors.
  • This review summarizes the state-of-the-art of small bowel nonendocrine tumors and the recent advancements in the knowledge of their molecular pathogenesis and cellular origin, with particular emphasis on stem cell research field.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Gastrointestinal Stromal Tumors / pathology. Humans. Lymphoma, Non-Hodgkin / pathology. Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496542.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 32
  •  go-up   go-down


17. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M, German Multicenter Study Group: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol; 2001 Sep 15;19(18):3861-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
  • PURPOSE: The study was initiated to obtain epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL).
  • Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not.
  • Within the intestine, the small bowel and the ileocecal region were involved in 8.6% and 7.0% of the cases, respectively.
  • Forty percent of PGL were of low-grade mucosa-associated lymphatic tissue type.
  • Most intestinal NHL were germinal-center lymphomas.
  • In gastric and ileocecal lymphoma, event-free (EFS) and overall survival (OS) were significantly higher as compared with the small intestine or MGI (median time of observation, 51 months).
  • In PGL, localized disease was prognostic for EFS and OS.
  • Numbers in intestinal lymphomas were too small for subanalyses.
  • Larger studies are needed for stages III and IV and for intestinal NHL.
  • A uniform reporting system for PGI NHL, in terms of definitions and histologic and staging classifications, is needed to facilitate comparison of treatment results.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11559724.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Krecic MR, Black SS: Epitheliotropic T-cell gastrointestinal tract lymphosarcoma with metastases to lung and skeletal muscle in a cat. J Am Vet Med Assoc; 2000 Feb 15;216(4):524-9, 517
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplastic lymphocytes infiltrated the epithelium and lamina propria of the stomach, small intestine, and large intestine.
  • Chemotherapy resulted in transient shrinkage of the lung and limb masses; however, these masses grew to approximately their original size within 2 weeks after initiation of treatment, and the cat was euthanatized.
  • [MeSH-major] Cat Diseases / pathology. Gastrointestinal Neoplasms / veterinary. Lung Neoplasms / veterinary. Lymphoma, Non-Hodgkin / veterinary. Muscle Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cats. Euthanasia / veterinary. Fatal Outcome. Hindlimb. Male. Muscle, Skeletal / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10687007.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Di Cataldo A, Lanteri R, Rapisarda C, Di Raimondo F, Licata A: Lymphoma of the cecum: a case report. Int Surg; 2002 Jan-Mar;87(1):12-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the cecum: a case report.
  • Non-Hodgkin lymphomas present a wider systemic diffusion than Hodgkin lymphomas.
  • The gastrointestinal tract is affected in 50% of the cases; the stomach is the first organ, followed by the small intestine and large intestine.
  • Colonoscopy showed a tumor in the cecum (diameter, approximately 10 cm) and the biopsy indicated lymphoma.
  • Through computed tomography, bone marrow biopsy, and measurement of beta2-microglobulin, complete staging was obtained.
  • Right hemicolectomy was immediately performed because the large tumor could determine intestinal occlusion.
  • Definitive diagnosis was non-Hodgkin lymphoma, type mucosa-associated lymphatic tissue B cells with a low grade of malignancy.
  • After surgery the patient underwent six courses of chemotherapy according to the CHOP scheme (750 mg/m2 cyclophosphamide, 1.4 mg/m2 vincristine, 50 mg/m2 adriamicin, and 80 mg prednisone).
  • Two years after surgery the patient shows no sign of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Cecal Neoplasms / pathology. Cyclophosphamide. Doxorubicin. Lymphoma, Non-Hodgkin / pathology. Prednisone. Vincristine. beta 2-Microglobulin / metabolism
  • [MeSH-minor] Colonoscopy. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12144183.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / beta 2-Microglobulin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Sasaki M, Matsue K, Takeuchi M, Mitome M, Hirose Y: Successful treatment of disseminated nasal NK/T-cell lymphoma using double autologous peripheral blood stem cell transplantation. Int J Hematol; 2000 Jan;71(1):75-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of disseminated nasal NK/T-cell lymphoma using double autologous peripheral blood stem cell transplantation.
  • Nasal natural killer (NK)/T-cell lymphoma is a rare disease with an aggressive clinical course.
  • Prognosis is generally poor and the disease is invariably fatal after systemic dissemination.
  • We report a patient with aggressive nasal NK/T-cell lymphoma who was resistant to therapy and developed systemic dissemination involving the intestine, skin, and stomach.
  • Epstein-Barr virus (EBV) was detected by Southern blotting with EBV-terminal repeat probe and by in situ EBV-encoded small nuclear early region-1 hybridization.
  • The patient was treated using double high-dose chemotherapy and autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • The patient obtained a complete remission and has been free of disease for 3.0 years since the second PBSCT.
  • These observations suggest that double high-dose chemotherapy with PBSCT support may be effective in resistant nasal NK/T-cell lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Killer Cells, Natural / pathology. Lymphoma, Non-Hodgkin / therapy. Lymphoma, T-Cell / therapy. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Herpesvirus 4, Human / genetics. Humans. Japan / ethnology. RNA, Viral / blood. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10729998.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


21. Souza MJ, Newman SJ, Greenacre CB, Avenell JS, Wall JS, Phillips JC, Fry MM, Donnell RL, Daniel GB: Diffuse intestinal T-cell lymphosarcoma in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata). J Vet Diagn Invest; 2008 Sep;20(5):656-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intestinal T-cell lymphosarcoma in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata).
  • A distended proventriculus and diffusely thickened loops of small intestine with irregular luminal surfaces were identified with contrast radiography and contrast computed tomography.
  • A micro positron emission tomography scan was performed with (18)F-fluorodeoxyglucose.
  • Diffuse intestinal T-cell lymphosarcoma was diagnosed based on histopathology and immunohistochemistry of full thickness small intestinal biopsies.
  • The patient was treated with a multidrug chemotherapy protocol with little to no effect.
  • Euthanasia was elected, and intestinal lymphosarcoma was confirmed on histopathology of necropsy intestinal samples; no other organs demonstrated neoplastic infiltration.
  • To the authors' knowledge, no reports are currently available detailing the clinical presentation or diagnosis of diffuse intestinal T-cell lymphosarcoma in any avian species.
  • [MeSH-major] Bird Diseases / pathology. Intestinal Neoplasms / veterinary. Lymphoma, Non-Hodgkin / veterinary. Lymphoma, T-Cell, Cutaneous / veterinary
  • [MeSH-minor] Animals. Euthanasia. Parrots. Positron-Emission Tomography / veterinary. Radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776105.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Khalid S, Adil SN, Vaziri IA: Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):88-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sites of presentation are bone, periosteum, soft tissue, lymph node, skin, and infrequently small intestine.
  • It can occur without blood or bone marrow manifestations of leukemia and in this case, the diagnosis is difficult.
  • Our patient was initially diagnosed as a case of T-cell non Hodgkin's lymphoma and received one cycle of CHOP with only transient improvement in his symptoms.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Histocytochemistry. Humans. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasms. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474271.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


23. Temmim L, Baker H, Amanguno H, Madda JP, Sinowatz F: Clinicopathological features of extranodal lymphomas: Kuwait experience. Oncology; 2004;67(5-6):382-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and epidemiological features of extranodal lymphomas in Kuwait.
  • Extranodal lymphomas accounted for 45% of all NHL observed during this time.
  • The most common lymphoma observed was diffuse large B-cell lymphoma (58.60%) followed by Burkitt s lymphoma (BL) (3.80%).
  • The most common extranodal sites were stomach (19.70%) and skin (17.80%) in the adult group, large intestine (29.80%) and small intestine (19.30%) in the pediatric age group.
  • Variations in treatment policies (single agent or combined chemotherapy, radiotherapy, combined modality treatment) adopted and changed during the time period of 16 years of this retrospective study were documented.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Female. Humans. Infant. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / pathology. Kuwait / epidemiology. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Registries. Retrospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel
  • (PMID = 15713994.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement